Angiotech partner completes first enrollment phase in next-generation TAXUS(R) Liberte(TM) coronary stent system registry
20 Juni 2005 - 8:45PM
PR Newswire (US)
Angiotech partner completes first enrollment phase in
next-generation TAXUS(R) Liberte(TM) coronary stent system registry
Study of first next-generation drug-eluting stent system on track
to become world's largest drug-eluting stent registry VANCOUVER,
June 20 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) corporate partner Boston
Scientific Corporation ("BSC") today announced that it has
completed enrollment in the transitional phase of the world's
largest drug-eluting stent registry. The OLYMPIA registry plans to
enroll more than 30,000 patients at more than 600 centers in the
United States, Europe and other international locations. The
registry is designed to collect and analyze "real-world" clinical
outcomes data for BSC's next- generation TAXUS(R) Liberte(TM)
paclitaxel-eluting stent system in the treatment of patients with
coronary artery disease in markets where the product is
commercially available. The TAXUS Liberte coronary stent system
will be the next generation to BSC's market-leading
paclitaxel-eluting coronary stent system, TAXUS(R) Express2(TM).
The Liberte stent features the Veriflex(TM) stent design, a highly
flexible cell geometry with thin struts and uniform cell
distribution. This new platform has been designed to offer improved
deliverability and conformability in challenging anatomy. It also
features the enhanced TrakTip(TM) catheter tip, mounted on the
Maverick2(TM) delivery catheter, designed to provide better lesion
crossability. In addition, TrakTip has a low lesion-entry profile,
also intended to further improve crossability. The registry will
enroll patients in five phases, corresponding to the commercial
introduction of the TAXUS Liberte system in different regions of
the world. The first, or transitional, phase involved the
enrollment of 500 patients from a limited number of international
markets in which BSC launched the TAXUS Liberte system in January
2005. This initial phase, for which enrollment was just completed,
will be followed by enrollment of approximately 30,000 patients
from a broader number of international markets and European markets
beginning this summer. The final U.S. phases are expected to start
enrollment in 2006. "We are very pleased that the OLYMPIA registry
has reached this important enrollment milestone and is on track to
become the world's largest drug- eluting stent registry," said Paul
LaViolette, Chief Operating Officer of BSC. "OLYMPIA will provide
valuable data about the real-world performance of our TAXUS Liberte
coronary stent system, the first next-generation drug-eluting stent
system." BSC received the CE Mark for the bare-metal Liberte stent
system in December 2003 and plans to launch the TAXUS
(drug-eluting) Liberte system in Europe this year. In April 2004,
BSC received U.S. Food and Drug Administration (FDA) approval for
its Liberte(TM) bare-metal coronary stent system. BSC has completed
enrollment in its ATLAS clinical trial, a pivotal study designed to
support FDA approval of the TAXUS Liberte stent system, and
anticipates FDA approval next year. The OLYMPIA registry was
formerly known as the OLYMPIC registry. BSC acquired worldwide
exclusive rights from Angiotech to use paclitaxel to coat its
coronary stent products and has co-exclusive rights to other
vascular and non-vascular products. Vancouver-based Angiotech
Pharmaceuticals, Inc. is a specialty pharmaceutical company
pioneering the combination of pharmaceutical compounds with medical
devices and biomaterials to both create novel solutions for poorly
addressed disease states and dramatically improve surgical
outcomes. To find out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Statements contained herein that are not
based on historical or current fact, including without limitation
statements containing the words "anticipates," "believes," "may,"
"continue," "estimate," "expects," "may" and "will" and words of
similar import, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which the Company operates;
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and
other claims asserted against the Company; and other factors
referenced in the Company's filings with the United States
Securities and Exchange Commission or the Canadian securities
regulators. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. The
Company does not assume the obligation to update any
forward-looking statements. CONTACTS: Todd Young, Vice President,
Investor Relations and Communications Angiotech Pharmaceuticals
(604) 221-7676 ext 6933 Rui Avelar, Senior Vice President, Medical
Affairs and Communications Angiotech Pharmaceuticals, Inc (604)
221-7676 ext 6996 DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: Todd Young, Vice President, Investor Relations and
Communications, Angiotech Pharmaceuticals, (604) 221-7676 ext 6933;
Rui Avelar, Senior Vice President, Medical Affairs and
Communications, Angiotech Pharmaceuticals, Inc, (604) 221-7676 ext
6996
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024